Results 271 to 280 of about 420,079 (341)
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Revisiting, reassessing, and reinterpreting 2 big ideas for family medicine: 2025 Dr Ian McWhinney Lecture Series. [PDF]
Stewart M.
europepmc +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Competition in human genetic technologies: The current US legal landscape. [PDF]
Rashid AI +3 more
europepmc +1 more source
Aim Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023 ...
Kyungyeon Jung +21 more
wiley +1 more source
Sustaining non-profit organizations: Strategic, managerial and financial perspectives. [PDF]
Harb Y, Khabbaz L, Azouri M, Estephan S.
europepmc +1 more source
Popularizing Wine Tasting Evaluation: An Adaptation of Mouthfeel Terminology. [PDF]
Moreno Rodríguez L +2 more
europepmc +1 more source
Evolution Equations on Co-evolving Graphs: Long-Time Behaviour and the Graph-Continuity Equation. [PDF]
Carrillo JA, Esposito A, Mikolás L.
europepmc +1 more source

